GleamWall
中文EN

AKBA Akebia Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1517022 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-12.4%
TTM net income YoY-180.2%
TTM EPS YoY-112.5%
Revenue 3-yr CAGR0.5%
Net income 3-yr CAGR—

Margins

Gross margin78.9%
Operating margin-15.7%
Net margin-22.6%
FCF margin7.0%
EBITDA margin-15.1%

Returns

ROE-143.8%
ROA-12.6%
ROIC (approx.)—
Asset turnover0.56x

Leverage & solvency

Liabilities / assets94.0%
Debt / equity2.47x
Current ratio1.36x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.35x
Accruals ratio-17.1%
Payout ratio—
Capex / revenue1.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$236.20M$160.18M
Cost of revenue$39.46M$63.18M
Gross profit$196.73M$97.00M
R&D expense$62.36M$37.65M
SG&A expense$107.48M$106.55M
Operating income$23.50M-$50.47M
Pretax income-$3.72M-$69.41M
Income tax$1.62M$0
Net income-$5.34M-$69.41M
EBITDA$24.77M-$49.01M
EPS (basic)-0.02-0.33
EPS (diluted)-0.02-0.33
Weighted avg. shares (diluted)257.16M210.95M
Balance sheet
Cash & equivalents$184.84M$53.55M
Receivables$47.03M$34.37M
Inventory$15.61M$16.24M
Current assets$252.96M$113.83M
PP&E, net$1.22M$2.20M
Goodwill$59.04M$59.04M
Intangibles—$0
Total assets$376.56M$220.67M
Current liabilities$162.94M$80.91M
Short-term debt$0$0
Long-term debt$48.25M$38.69M
Total debt$48.25M$38.69M
Total liabilities$343.95M$269.86M
Shareholders' equity$32.61M-$49.19M
Net debt-$136.59M-$14.86M
Shares outstanding265.42M224.85M
Cash flow statement
Operating cash flow$67.99M-$40.66M
Capital expenditure$291,000$33,000
Free cash flow$67.70M-$40.69M
Investing cash flow-$7.93M-$33,000
Financing cash flow$72.93M$49.66M
Depreciation & amortization$1.27M$1.46M
Stock-based compensation$11.28M$7.78M

Free plan shows the latest 2 periods; Pro shows all 14 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.